Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06658535
PHASE1

A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress

Sponsor: NuvOx LLC

View on ClinicalTrials.gov

Summary

EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.

Official title: Novel Oxygen Therapeutic NanO2 for Mild Respiratory Distress in Phase 1b

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2025-03-13

Completion Date

2026-12

Last Updated

2026-01-28

Healthy Volunteers

No

Interventions

DRUG

dodecafluoropentane (0.025 mL/kg)

dodecafluoropentane (0.025 mL/kg)

DRUG

dodecafluoropentane (0.032 mL/kg)

dodecafluoropentane (0.032 mL/kg)

DRUG

dodecafluoropentane (0.050 mL/kg)

dodecafluoropentane (0.050 mL/kg)

Locations (2)

Grey Nun Community Hospital

Edmonton, Alberta, Canada

Hôpital Maisonneuve Rosemont

Montreal, Quebec, Canada